Status:
UNKNOWN
Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo
Lead Sponsor:
Assiut University
Conditions:
Generalized Vitiligo
Eligibility:
All Genders
12+ years
Phase:
PHASE4
Brief Summary
Vitiligo is a chronic disorder of pigmentation characterized by the development of white macules on the skin due to loss of epidermal melanocytes. It affects approximately 0.5%-2% of general populatio...
Detailed Description
Bimatoprost 0.03% ophthalmic solution is a synthetic prostaglandin F2 alpha analog that is approved for the treatment of glaucoma and eyelashes hypotrichosis (Lee et al, 2017). Cutaneous hyperpigmenta...
Eligibility Criteria
Inclusion
- Patients older than 12.
- Patients with non-segmental vitiligo.
- Lesions stable for at least one year.
- Patients who were unresponsive to medical treatment or photo therapy for at least 3 months.
- No sex or site predilection.
- Bilateral and symmetrical lesions with maximum size of 10×10 cm.
Exclusion
- Patients with active infection.
- Patients with sensitivity to bimatoprost or photosensitivity.
- Patients with history or active skin cancer.
- Pregnant or lactating females.
Key Trial Info
Start Date :
May 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03487042
Start Date
May 1 2018
End Date
December 1 2019
Last Update
April 3 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.